Mankind Pharma Plans 70% Belgian Biotech Acquisition

Business Standard reports that Mankind Pharma plans to acquire a 70% stake in a Belgian biotechnology firm for €48 million. The proposed transaction marks Mankind Pharma’s entry into next-generation CAR-T cancer therapies, according to the publication.

Majority stake in Belgian biotech firm

The reported deal would give Mankind Pharma a majority position in the Belgian biotech firm. Business Standard identified the value of the planned acquisition as €48 million and described the transaction as part of the company’s global innovation ambitions.

The supplied report does not identify the Belgian biotech firm by name or provide additional transaction terms. It does, however, establish the proposed 70% stake and the stated value of €48 million.

CAR-T therapies at the center of the transaction

Business Standard characterized the acquisition as Mankind Pharma’s entry into next-generation CAR-T cancer therapies. CAR-T is the therapeutic area specifically connected to the proposed transaction in the report.

For pharmaceutical and biotech sales professionals monitoring oncology-related company activity, the announcement centers on a majority-stake acquisition and a stated move into CAR-T cancer therapies. The report also places the transaction within Mankind Pharma’s broader global innovation ambitions.

Reported scope of the announcement

Business Standard’s report focuses on the planned acquisition, Mankind Pharma’s proposed 70% ownership position, the €48 million value, and the connection to next-generation CAR-T cancer therapies. No further details are included in the supplied evidence regarding the firm’s products, development programs, commercial operations, or timing of the transaction.

The announcement is therefore a notable reported development for those following oncology, biotechnology, and cross-border pharmaceutical transactions.